- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05165056
Photobiomodulation Therapy in the Prevention and Management of Radiotherapy-induced Vaginal Toxicity (GynLight)
September 28, 2023 updated by: Jessa Hospital
Evaluating the Feasibility and Efficacy of Photobiomodulation Therapy in the Prevention and Management of Radiotherapy-induced Vaginal Toxicity: a Randomized Controlled Trial
This study aims to investigate the effectiveness of photobiomodulation therapy (PBMT) in the prevention and management of radiotherapy-induced vaginal toxicity (RIVT).
Therefore, we hypothesize that PBMT can reduce the severity of RIVT in gynecological cancer patients, increasing the patient's QoL and sexual functioning.
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Detailed Description
The global cancer burden keeps rising, and the accompanied side effects remain a significant concern.
This project focuses on one of such complications: radiotherapy-induced vaginal toxicity (RIVT).
The use of external and internal radiotherapy in gynecological cancers can severely impact the patient's vaginal function.
This influences the patient's quality of life (QoL), as it significantly limits sexual intercourse and further physical examination.
Management of RIVT urgently requires a comprehensive approach.
Photobiomodulation therapy (PBMT) is a non-invasive form of phototherapy that utilizes visible and/or near-infrared light to trigger a cascade of intracellular reactions.
PBMT can be used to improve wound healing, and to reduce pain, inflammation, and edema.
Literature shows that PBMT can be used for treating the genitourinary syndrome of menopause as it stimulates the synthesis of collagen and elastin and promotes vasodilation in the vaginal submucosa.
To date, no clinical trials have investigated the positive effects of PBMT on RIVT.
Study Type
Interventional
Enrollment (Estimated)
62
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Jeroen Mebis, Prof. Dr.
- Phone Number: +32 11 33 72 21
- Email: jeroen.mebis@jessazh.be
Study Contact Backup
- Name: Marithé Claes, MSc
- Phone Number: +32 11 33 72 39
- Email: marithe.claes@uhasselt.be
Study Locations
-
-
Limburg
-
Genk, Limburg, Belgium, 3600
- Recruiting
- Ziekenhuis Oost-Limburg
-
Contact:
- Evelyn Van de Werf, Dr.
- Phone Number: +32 89 32 65 61
- Email: Evelyn.VandeWerf@zol.be
-
Contact:
- Marithé Claes, MSc
- Phone Number: +32 11 33 72 39
- Email: marithe.claes@uhasselt.be
-
Hasselt, Limburg, Belgium, 3500
- Recruiting
- Jessa Hospital
-
Sub-Investigator:
- Philippe Bulens, Dr.
-
Contact:
- Jeroen Mebis, Prof. Dr.
- Phone Number: +32 11 33 72 21
- Email: jeroen.mebis@jessazh.be
-
Contact:
- Marithé Marithé, MSc
- Phone Number: +32 11 33 72 39
- Email: marithe.claes@uhasselt.be
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Diagnosed with endometrial cancer
- Scheduled for external beam radiotherapy (EBRT), intracavitary brachytherapy (BT), or a combination
- Age ≥ 18 years
- Able to comply to the study protocol
- Able to sign written informed consent
Exclusion Criteria:
- Metastatic disease
- Pregnancy
- Diagnosis of vaginal stenosis before radiotherapy (RT)
- Previous pelvic tumor or pelvic RT
- Interruption of RT for more than five sessions
- Severe psychological disorder or dementia.
- Inability to speak and understand Dutch
- Substance abuse patients or patients with medical, psychological or social conditions that may interfere with the patient's participation in the study or evaluation of the study results as judged by the investigator
- Any condition that is unstable or could affect the safety of the patient and their compliance in the study as judged by the investigator
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Treatment group
Patients allocated to the treatment group will receive institutional standard vaginal care in combined with twice weekly PBMT sessions during the radiotherapy course and until two weeks after the end of radiotherapy.
|
INTIMILEDS® is a photobiomodulation device designed for intravaginal use.
It's design permits an irradiation of the whole vaginal wall, the vulva, and the cervix, with a constant intensity.
|
No Intervention: Control group
Patients allocated to the control group will receive institutional standard vaginal care.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
CTCAE-score
Time Frame: Baseline
|
The physician will score the patient's vaginal dryness, discharge, inflammation, stricture, pain and hemorrhage according to the Common Terminology Criteria for Adverse Events (CTCAE)
|
Baseline
|
CTCAE-score
Time Frame: Two weeks post radiotherapy
|
The physician will score the patient's vaginal dryness, discharge, inflammation, stricture, pain and hemorrhage according to the Common Terminology Criteria for Adverse Events (CTCAE)
|
Two weeks post radiotherapy
|
CTCAE-score
Time Frame: Three months post radiotherapy
|
The physician will score the patient's vaginal dryness, discharge, inflammation, stricture, pain and hemorrhage according to the Common Terminology Criteria for Adverse Events (CTCAE)
|
Three months post radiotherapy
|
RIVT symptoms
Time Frame: Baseline
|
The patient will score their symptoms (dryness, pruritus, discharge, hemorrhage and a burning sensation) via a numeric rating scale (NRS) ranging from 0 (symptom absent) to 10 (most severe form).
|
Baseline
|
RIVT symptoms
Time Frame: Final radiotherapy session
|
The patient will score their symptoms (dryness, pruritus, discharge, hemorrhage and a burning sensation) via a NRS ranging from 0 (symptom absent) to 10 (most severe form).
|
Final radiotherapy session
|
RIVT symptoms
Time Frame: Two weeks post radiotherapy
|
The patient will score their symptoms (dryness, pruritus, discharge, hemorrhage and a burning sensation) via a NRS ranging from 0 (symptom absent) to 10 (most severe form).
|
Two weeks post radiotherapy
|
RIVT symptoms
Time Frame: Three months post radiotherapy
|
The patient will score their symptoms (dryness, pruritus, discharge, hemorrhage and a burning sensation) via a NRS ranging from 0 (symptom absent) to 10 (most severe form).
|
Three months post radiotherapy
|
RIVT symptoms
Time Frame: One year post radiotherapy
|
The patient will score their symptoms (dryness, pruritus, discharge, hemorrhage and a burning sensation) via a NRS ranging from 0 (symptom absent) to 10 (most severe form).
|
One year post radiotherapy
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Vaginal health index (VHI)
Time Frame: Baseline
|
A clinical exam will be performed by the physician to evaluate vaginal elasticity, vaginal secretion, pH, epithelial integrity and moisture.
These five parameters will be scored on the on the VHI, from 1 (severe symptoms) to 5 (normal vaginal health).
A total score can be calculated by adding the scores of the different parameters
|
Baseline
|
Vaginal health index (VHI)
Time Frame: Two weeks post radiotherapy
|
A clinical exam will be performed by the physician to evaluate vaginal elasticity, vaginal secretion, pH, epithelial integrity and moisture.
These five parameters will be scored on the on the VHI, from 1 (severe symptoms) to 5 (normal vaginal health).
A total score can be calculated by adding the scores of the different parameters
|
Two weeks post radiotherapy
|
Vaginal health index (VHI)
Time Frame: Three months post radiotherapy
|
A clinical exam will be performed by the physician to evaluate vaginal elasticity, vaginal secretion, pH, epithelial integrity and moisture.
These five parameters will be scored on the on the VHI, from 1 (severe symptoms) to 5 (normal vaginal health).
A total score can be calculated by adding the scores of the different parameters
|
Three months post radiotherapy
|
Pain score
Time Frame: Baseline
|
A NRS (0, no pain to 10, the most severe pain) will be used to evaluate the patient's pain level due to the RIVT.
|
Baseline
|
Pain score
Time Frame: Two weeks post radiotherapy
|
A NRS (0, no pain to 10, the most severe pain) will be used to evaluate the patient's pain level due to the RIVT.
|
Two weeks post radiotherapy
|
Pain score
Time Frame: Three months post radiotherapy
|
A NRS (0, no pain to 10, the most severe pain) will be used to evaluate the patient's pain level due to the RIVT.
|
Three months post radiotherapy
|
Pain score
Time Frame: One year post radiotherapy
|
A NRS (0, no pain to 10, the most severe pain) will be used to evaluate the patient's pain level due to the RIVT.
|
One year post radiotherapy
|
Quality of Life score
Time Frame: Baseline
|
The Female Sexual Function Index (FSFI) is a multidimensional, self-reported questionnaire that evaluates the patient's sexual functioning.
The questionnaire consists of 19 questions, divided into six subscales (sexual desire, sexual arousal, lubrication, orgasms, sexual gratification and pain during intercourse).
The total score ranges from 2 (severely compromised sexual functioning) to 36 (excellent sexual functioning).
|
Baseline
|
Quality of Life score
Time Frame: Two weeks post radiotherapy
|
The European Organization for Research and Treatment for Cancer Quality of Life Questionnaires (EORTC QLQ) will be used to assess the patients' quality of life.
|
Two weeks post radiotherapy
|
Quality of Life score
Time Frame: Three months post radiotherapy
|
The European Organization for Research and Treatment for Cancer Quality of Life Questionnaires (EORTC QLQ) will be used to assess the patients' quality of life.
|
Three months post radiotherapy
|
Quality of Life score
Time Frame: One year post radiotherapy
|
The European Organization for Research and Treatment for Cancer Quality of Life Questionnaires (EORTC QLQ) will be used to assess the patients' quality of life.
|
One year post radiotherapy
|
Sexual functioning score
Time Frame: Baseline
|
The Female Sexual Function Index (FSFI) is a multidimensional, self-reported questionnaire that evaluates the patient's sexual functioning.
The questionnaire consists of 19 questions, divided into six subscales (sexual desire, sexual arousal, lubrication, orgasms, sexual gratification and pain during intercourse).
The total score ranges from 2 (severely compromised sexual functioning) to 36 (excellent sexual functioning).
|
Baseline
|
Sexual functioning score
Time Frame: Two weeks post radiotherapy
|
The Female Sexual Function Index (FSFI) is a multidimensional, self-reported questionnaire that evaluates the patient's sexual functioning.
The questionnaire consists of 19 questions, divided into six subscales (sexual desire, sexual arousal, lubrication, orgasms, sexual gratification and pain during intercourse).
The total score ranges from 2 (severely compromised sexual functioning) to 36 (excellent sexual functioning).
|
Two weeks post radiotherapy
|
Sexual functioning score
Time Frame: Three months post radiotherapy
|
The Female Sexual Function Index (FSFI) is a multidimensional, self-reported questionnaire that evaluates the patient's sexual functioning.
The questionnaire consists of 19 questions, divided into six subscales (sexual desire, sexual arousal, lubrication, orgasms, sexual gratification and pain during intercourse).
The total score ranges from 2 (severely compromised sexual functioning) to 36 (excellent sexual functioning).
|
Three months post radiotherapy
|
Sexual functioning score
Time Frame: One year post radiotherapy
|
The Female Sexual Function Index (FSFI) is a multidimensional, self-reported questionnaire that evaluates the patient's sexual functioning.
The questionnaire consists of 19 questions, divided into six subscales (sexual desire, sexual arousal, lubrication, orgasms, sexual gratification and pain during intercourse).
The total score ranges from 2 (severely compromised sexual functioning) to 36 (excellent sexual functioning).
|
One year post radiotherapy
|
Sexual distress score
Time Frame: Baseline
|
The multidimensional, self-reported Female Sexual Distress Scale-Revised 2005 (FSDS-R) questionnaire will be used to evaluate the patient's sexual distress.
This questionnaire consists of 13 items scored from 0 (never occurring) to 4 (always occurring).
A score of 11 or more effectively discriminates between patients with female sexual distress and patients without distress.
|
Baseline
|
Sexual distress score
Time Frame: Two weeks post radiotherapy
|
The multidimensional, self-reported Female Sexual Distress Scale-Revised 2005 (FSDS-R) questionnaire will be used to evaluate the patient's sexual distress.
This questionnaire consists of 13 items scored from 0 (never occurring) to 4 (always occurring).
A score of 11 or more effectively discriminates between patients with female sexual distress and patients without distress.
|
Two weeks post radiotherapy
|
Sexual distress score
Time Frame: Three months post radiotherapy
|
The multidimensional, self-reported Female Sexual Distress Scale-Revised 2005 (FSDS-R) questionnaire will be used to evaluate the patient's sexual distress.
This questionnaire consists of 13 items scored from 0 (never occurring) to 4 (always occurring).
A score of 11 or more effectively discriminates between patients with female sexual distress and patients without distress.
|
Three months post radiotherapy
|
Sexual distress score
Time Frame: One year post radiotherapy
|
The multidimensional, self-reported Female Sexual Distress Scale-Revised 2005 (FSDS-R) questionnaire will be used to evaluate the patient's sexual distress.
This questionnaire consists of 13 items scored from 0 (never occurring) to 4 (always occurring).
A score of 11 or more effectively discriminates between patients with female sexual distress and patients without distress.
|
One year post radiotherapy
|
Satisfaction score
Time Frame: Two weeks post radiotherapy
|
The patients will be asked to evaluate the general pleasantness and soothing effect of the therapeutic intervention.
Furthermore, they will be asked to score their global satisfaction with the therapeutic intervention.
The patients will score their satisfaction regarding their treatment on the NRS scale 0 (totally not satisfied) to 10 (very satisfied).
|
Two weeks post radiotherapy
|
Satisfaction score
Time Frame: Three months post radiotherapy
|
The patients will be asked to evaluate the general pleasantness and soothing effect of the therapeutic intervention.
Furthermore, they will be asked to score their global satisfaction with the therapeutic intervention.
The patients will score their satisfaction regarding their treatment on the NRS scale 0 (totally not satisfied) to 10 (very satisfied).
|
Three months post radiotherapy
|
Satisfaction score
Time Frame: One year post radiotherapy
|
The patients will be asked to evaluate the general pleasantness and soothing effect of the therapeutic intervention.
Furthermore, they will be asked to score their global satisfaction with the therapeutic intervention.
The patients will score their satisfaction regarding their treatment on the NRS scale 0 (totally not satisfied) to 10 (very satisfied).
|
One year post radiotherapy
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
General patient-, disease-, and treatment-related information
Time Frame: Baseline
|
General and medical information will be collected through a short patient questionnaire in order to assess intrinsic risk factors (e.g.
age and smoking history).
Information regarding the disease- and treatment-related risk factors will be collected through medical records (e.g., tumour type and stage).
|
Baseline
|
General patient-, disease-, and treatment-related information
Time Frame: Three months post radiotherapy
|
General and medical information will be collected through a short patient questionnaire in order to assess intrinsic risk factors (e.g.
age and smoking history).
Information regarding the disease- and treatment-related risk factors will be collected through medical records (e.g., tumour type and stage).
|
Three months post radiotherapy
|
General patient-, disease-, and treatment-related information
Time Frame: One year post radiotherapy
|
General and medical information will be collected through a short patient questionnaire in order to assess intrinsic risk factors (e.g.
age and smoking history).
Information regarding the disease- and treatment-related risk factors will be collected through medical records (e.g., tumour type and stage).
|
One year post radiotherapy
|
Cancer relapse or recurrence
Time Frame: One year post radiotherapy
|
The posibility of cancer relapse or recurrence will be evaluated using the patients' medical records.
|
One year post radiotherapy
|
Cancer relapse or recurrence
Time Frame: Two years post radiotherapy
|
The posibility of cancer relapse or recurrence will be evaluated using the patients' medical records.
|
Two years post radiotherapy
|
Cancer relapse or recurrence
Time Frame: Three years post radiotherapy
|
The posibility of cancer relapse or recurrence will be evaluated using the patients' medical records.
|
Three years post radiotherapy
|
Cancer relapse or recurrence
Time Frame: Four years post radiotherapy
|
The posibility of cancer relapse or recurrence will be evaluated using the patients' medical records.
|
Four years post radiotherapy
|
Cancer relapse or recurrence
Time Frame: Five years post radiotherapy
|
The posibility of cancer relapse or recurrence will be evaluated using the patients' medical records.
|
Five years post radiotherapy
|
Radiotherapy dose
Time Frame: Final radiotherapy session
|
During the delineation for RT planning, a vaginal reference point will be constructed.
An anatomical vaginal reference point was defined at the level of the Posterior-Inferior Border of Symphysis (PIBS), plus two points ±2 cm (mid/introitus vagina).
For BT extra points were selected for the upper vagina at 12/3/6/9 o'clock, at the vaginal surface and 5 mm depth.
Dose reporting to these vaginal reference points will be done and the dose to these reference points will then be correlated with RIVT.
|
Final radiotherapy session
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Jeroen Mebis, Prof. Dr., Jessa Hospital
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
August 24, 2022
Primary Completion (Estimated)
January 1, 2030
Study Completion (Estimated)
January 1, 2030
Study Registration Dates
First Submitted
November 23, 2021
First Submitted That Met QC Criteria
December 6, 2021
First Posted (Actual)
December 21, 2021
Study Record Updates
Last Update Posted (Actual)
September 29, 2023
Last Update Submitted That Met QC Criteria
September 28, 2023
Last Verified
September 1, 2023
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2021/099
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Radiotherapy Side Effect
-
National Cancer Institute, EgyptUnknownRadiotherapy Side EffectEgypt
-
Tanta UniversityCompletedRadiotherapy Side EffectEgypt
-
Centre hospitalier de l'Université de Montréal...RecruitingCancer | Radiotherapy Side EffectCanada
-
Centre hospitalier de l'Université de Montréal...RecruitingCancer | Radiotherapy Side EffectCanada
-
Centre Leon BerardRecruitingCancer | Radiotherapy Side EffectFrance
-
Medical University of ViennaRecruiting
-
Centre Francois BaclesseCompletedRadiotherapy Side Effect | Merkel CarcinomaFrance
-
Umeå UniversityCompletedPediatric ALL | Radiotherapy Side Effect
-
Latin American Cooperative Oncology GroupRecruitingRadiotherapy Side EffectBrazil
-
Samsung Medical CenterRecruitingRadiotherapy Side EffectKorea, Republic of